This study is examining the effectiveness of a drug called opevesostat compared to other hormonal treatments like abiraterone acetate or enzalutamide. It focuses on men with metastatic castration-resistant prostate cancer (mCRPC), which is prostate cancer that has spread and doesn't respond to treatments lowering testosterone. The goal is to see if opevesostat helps patients live longer without the cancer getting worse, checked through scans and overall survival rates.
**Key Points for Participants:**
- Study Duration: The study will require visits over a period of time, but exact duration isn't specified.
- Eligibility: You must have confirmed prostate cancer that has spread and have been treated with one hormonal agent before.
- Risks and Benefits: The study will assess safety and effectiveness, but there might be risks or side effects involved.
If you have a history of certain health issues like heart problems, seizures, or active infections, you may not be eligible. Discuss with your doctor to see if joining this study is right for you.
How understandable was the trial content above?
Hard to understand
Easy to understand